Literature DB >> 10512083

Effects of rolipram on the elevated plus-maze test in rats: a preliminary study.

J S Silvestre1, A G Fernández, J M Palacios.   

Abstract

The objective of the present study was to assess the behavioural effects of rolipram, a specific cAMP phosphodiesterase (PDE4) inhibitor, in the elevated plus-maze (EPM) test in rats. Results showed that rolipram at the highest dose tested (0.1 mg/kg) increased the percentage of both time spent and entries into open arms, although a decrease of locomotor activity in the EPM test was also observed. In contrast, diazepam (3.0 mg/kg) exhibited the typical profile of an anxiolytic in the EPM test, increasing the percentage of time spent and entries into open arms as well as locomotor activity. A posterior statistical analysis, however, established that the effects of both rolipram and diazepam on parameters denoting anxiolytic-like activity were statistically independent from those reflecting locomotor activity reduction. Furthermore, the effects of both rolipram and diazepam were shown to be distinct from those exhibited by tricyclic antidepressant imipramine which did not show any anxiolytic-like effects in the EPM test, although a reduction of locomotor activity was also detected. Although these preliminary results suggest that rolipram may have some anxiolytic-like properties on the EPM test in rats, such an interpretation should be taken cautiously due to the observed effects on locomotor activity, which could complicate the interpretation of results from rolipram and other PDE4 inhibitors in the current test and in other anxiety animal models.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10512083     DOI: 10.1177/026988119901300309

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  18 in total

1.  Postinjury treatment with rolipram increases hemorrhage after traumatic brain injury.

Authors:  C M Atkins; Y Kang; C Furones; J S Truettner; O F Alonso; W D Dietrich
Journal:  J Neurosci Res       Date:  2012-04-26       Impact factor: 4.164

2.  Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats.

Authors:  Han-Ting Zhang; Ying Huang; Neesha U Suvarna; Chengjun Deng; Alicia M Crissman; Allen T Hopper; Michael De Vivo; Gregory M Rose; James M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2005-01-26       Impact factor: 4.530

3.  Attenuation of ethanol abstinence-induced anxiety- and depressive-like behavior by the phosphodiesterase-4 inhibitor rolipram in rodents.

Authors:  Mei-Fang Gong; Rui-Ting Wen; Ying Xu; Jian-Chun Pan; Ning Fei; Yan-Meng Zhou; Jiang-Ping Xu; Jian-Hui Liang; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2017-07-27       Impact factor: 4.530

4.  A new model of Pde4d deficiency: genetic knock-down of PDE4D enzyme in rats produces an antidepressant phenotype without spatial cognitive effects.

Authors:  T L Schaefer; A A Braun; R M Amos-Kroohs; M T Williams; E Ostertag; C V Vorhees
Journal:  Genes Brain Behav       Date:  2012-05-08       Impact factor: 3.449

5.  Chronic Galphas signaling in the striatum increases anxiety-related behaviors independent of developmental effects.

Authors:  Christopher Favilla; Ted Abel; Michele P Kelly
Journal:  J Neurosci       Date:  2008-12-17       Impact factor: 6.167

6.  Inactivation of Pde8b enhances memory, motor performance, and protects against age-induced motor coordination decay.

Authors:  L-C L Tsai; G C-K Chan; S N Nangle; M Shimizu-Albergine; G L Jones; D R Storm; J A Beavo; L S Zweifel
Journal:  Genes Brain Behav       Date:  2012-09-04       Impact factor: 3.449

Review 7.  The cyclic AMP phenotype of fragile X and autism.

Authors:  Daniel J Kelley; Anita Bhattacharyya; Garet P Lahvis; Jerry C P Yin; Jim Malter; Richard J Davidson
Journal:  Neurosci Biobehav Rev       Date:  2008-06-17       Impact factor: 8.989

8.  Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B).

Authors:  Han-Ting Zhang; Ying Huang; Anbrin Masood; Lisa R Stolinski; Yunfeng Li; Lei Zhang; Daniel Dlaboga; S-L Catherine Jin; Marco Conti; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2007-08-15       Impact factor: 7.853

Review 9.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

10.  Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus.

Authors:  Yun-Feng Li; Ying Huang; Simon L Amsdell; Lan Xiao; James M O'Donnell; Han-Ting Zhang
Journal:  Neuropsychopharmacology       Date:  2009-06-10       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.